Drug intelligence / Profile preview

Idomarine-M

Development stage: Unknown
Lead developer: MTI Medical
Modality: Small Molecules
Administration: Oral

Overview

Idomarine-M is a nutraceutical combination product developed by MTI Medical, primarily indicated for the management of Polycystic Ovary Syndrome (PCOS), insulin resistance, and related hormonal dysregulation and infertility. The formulation consists of an iodine complex, myoinositol, L-methyl folate, and vitamin D. It is designed to support metabolic and reproductive health by targeting the sodium-iodide symporter (NIS) to improve iodine transport, modulating PPARγ activity, and enhancing insulin signaling pathways. The product is marketed in a sachet form for oral administration.

Brand names: Idomarine-M
Other names: Idomarine-M Sachet

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)NIS (Human sodium iodide symporter)

Beyond the preview

Go deeper on Idomarine-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idomarine-M.

Explore the full profile